Zdrowie i gospodarka · 25/08/2016

FDA Releases Guidance on Refusing Abbreviated New Drug Applications for Lack of Impurity Limits Justification

The FDA has issued a guidance document to help pharmaceutical companies prepare for abbreviated new drug applications (ANDAs) by clarifying the requirements for impurity limits justification, which can lead to the FDA refusing to receive the application.